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Review
Introduction
How important is it to treat subclinical hypothy-
roidism (SCH) ? This question leads to a chain of con-
troversial discussions. SCH is a condition with an ele-
vated thyroid-stimulating hormone (TSH) in the set-
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Aim: Research shows that subclinical hypothyroidism (SCH) is related to an increased carotid 
intima–media thickness (CIMT), a surrogate marker of subclinical cardiovascular disease (CVD). It 
is controversial whether or not SCH should be treated to reduce CVD morbidity and mortality. This 
meta-analysis aimed to determine whether SCH is associated with an increase in CIMT as compared 
to Euthyroidism (EU) and whether thyroxin (T4) treatment in SCH can reverse the change in CIMT.
Methods: Two independent reviewers conducted an extensive database research up to December 
2016. A total of 12 clinical trials discussed the effect of Thyroxin on CIMT values at pre- and post-
treatment in subjects with SCH.
Results: CIMT was significantly higher among SCH (n?280) as compared to EU controls (n?263) 
at baseline; the pooled weighted mean difference (WMD) of CIMT was 0.44 mm [95% confidence 
interval (CI) 0.14, 0.74], p?0.004; I2?65%. After treatment with thyroxin in subjects with SCH 
(n?314), there was a statistically significant decrease in CIMT from pre- to post-treatment; the 
pooled WMD of CIMT decrease was [WMD ?0.32; 95% CI (?0.47, ?0.16), p??0.0001; I2?2%], 
and it was no longer different from EU controls [WMD 0.13 mm; 95% CI (?0.04, 0.30); p?0.14; 
I2?27%]. The total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL) were 
higher in SCH as compared to EU controls and decreased significantly after treatment with thyroxin.
Conclusion: This meta-analysis shows that thyroxin therapy in subjects with SCH significantly 
decreases CIMT and improves lipid profile, modifiable CVD risk factors. Thyroid hormone replace-
ment in subjects with SCH may play a role in slowing down or preventing the progression of athero-
sclerosis.
Key words: Subclinical hypothyroidism, Euthyroid/Euthyroidism, Carotid intima–media thickness, 
Thyroxin treatment, Dyslipidemia, Clinical trials, Meta-analysis
Address for correspondence: Khurram Nasir, Center for Health-
care Advancement & Outcomes, Baptist Health South Florida, 
9555 SW 162nd Ave. MAB, Suite 103. Miami. FL 33196, USA
Email: KhurramN@baptisthealth.net
Received: January 19, 2017
Accepted for publication: March 20, 2017
Copyright©2017 Japan Atherosclerosis Society
This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
???????????
644
with SCH during a follow-up period.” We selected 
original published clinical trials with no language and 
regional limitations. According to the hypothesis, we 
defined a strict inclusion and exclusion criteria as 
described below.
Inclusion Criteria were as Follows
(1) Studies investigating subjects with SCH (the 
mean pretreatment basal serum TSH concentration 
must have been above the upper limit of normal for 
the assay used in the study, but less than 20 mU/L 
along with a normal T4 level) and comparing them 
with subjects with EU; (2) Use of the ultrasound 
method to measure CIMT both in subjects with SCH 
and EU at baseline; and (3) Use of the ultrasound 
method to measure CIMT in subjects with SCH at 
pre- and post-treatment with thyroxin along a follow-
up period. We included studies that discussed demo-
graphically, anthropometrically, and metabolically 
matched SCH and EU control groups to discuss the 
effect of SCH on CIMT and the role of thyroxin 
treatment on CIMT reduction in subjects with SCH.
We excluded all studies that discussed subjects 
with chronic diseases/risk factors that can potentially 
affect CIMT and thyroid function tests. Exclusion cri-
teria were as follows: (1) Use of overt clinical hypothy-
roidism/hyperthyroidism subjects; (2) Use of subjects 
on any medications to treat hypo and hyper functions 
of thyroid, including thyroid cancer; (3) Use of any 
subjects with average TSH ?20 (mIU/l); (4) Use of 
any subjects with established coronary artery disease 
(CAD), congestive heart failure (CHF), obesity (BMI 
≥30 kg/m2), chronic liver disease, chronic kidney fail-
ure, chronic inflammatory diseases, hypophyseal 
insufficiency, or any type of cancer; (5) Use of any 
pregnant, lactating, or menopausal women; (6) Use of 
any subject using medications that can potentially 
alter thyroid function tests (e.g., amiodarone, carbam-
azepine, carbidopa, phenytoin, furosemide, haloperi-
dol, heparin, interferon, levodopa, Lithium, metoclo-
pramide, propranolol, primidone, rifampicin, and val-
proic acid.) (7) Use of any subject using medications 
that can potentially affect hormonal changes in the 
body (e.g., antidiabetics, glucocorticoid therapy, OCP, 
steroids, GnRH agonists and antagonists, insulin-sen-
sitizing drugs, antiandrogens, and aspirin), as well as 
affect blood pressure (anti-hypertensives) or lipid lev-
els (anti-hyperlipidemics); and (8) Use of different 
therapeutic approaches apart from thyroxin/T4 treat-
ment of subjects with SCH.
Information Sources and Search Strategy
An extensive literature search, not limited by lan-
guage and regions, was performed, which was directed 
ting of normal free thyroid hormone levels, both FT3 
and FT41). In the recent past, the detection of SCH 
has been increasing with evolving diagnostic tests. The 
prevalence of SCH is greater than that of type 2 dia-
betes mellitus (estimated to be 5 –10%) and with an 
increased occurrence among females and the elderly2-4). 
The prevalence of SCH is almost up to 20% in 
females older than 60 years2).
SCH has also been considered to increase the risk 
of atherosclerosis alongside overt hypothyroidism5, 6). 
The association of overt hypothyroidism with athero-
sclerotic disease has been well established, and treating 
those patients with levothyroxine has shown proven 
benefits in reducing cardiovascular risk7). There is evi-
dence that SCH had effects on some important car-
diovascular risk factors, such as high blood pressure, 
dyslipidemia, and altered coagulability8, 9). However, 
how significant a role does SCH play as an indepen-
dent risk factor for atherosclerosis was debatable, until 
a recent population-based study proved otherwise10, 11).
Carotid Intima –media thickness (CIMT), mea-
sured using carotid ultrasonography, is trusted to be a 
good marker of atherosclerotic changes in early stages 
apart from being accepted as a surrogate endpoint for 
cardiovascular events12, 13). Many studies have shown 
that SCH is independently related to a significant incr-
ease in CIMT in relatively healthy subjects when com-
pared with euthyroid (EU) healthy matched groups14-19). 
Several studies, including some randomized controlled 
trials, have shown reduced cardiovascular risk, includ-
ing a significant reduction in CIMT in subjects with 
SCH treated with levothyroxin15, 17, 18, 20-28).
The primary focus of this review and meta-anal-
ysis is to determine the differences of CIMT between 
subjects with SCH and EU controls at baseline as well 
as to demonstrate the effects of thyroxine treatment 
on CIMT reduction from pre-to-post treatment after 
a follow-up period. We hypothesized that “thyroxin 
treatment in subjects with SCH causes a decrease in 
CIMT values from pre-to-post treatment.”
Methods
We conducted this systematic review and meta-
analysis using the PRISMA statement as guideline29).
Eligibility Criteria
In this systematic review and meta-analysis, we 
included the clinical trials that reported the treatment 
of subjects with SCH and discussed the effects of thy-
roxin treatment on CIMT reduction in subjects with 
SCH from pre- to post-treatment during a follow-up 
period. Our hypothesis was to analyze “the effects of 
thyroxin treatment on CIMT reduction in patients 
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reference sections of the finally selected studies were 
screened for additional eligible studies. In rare cases, 
authors of the relevant studies were contacted when 
more information or clarification was needed. Fig.1 
shows the PRISMA flow diagram of the effect of thy-
roxin treatment on the reduction of CIMT values in 
subjects with SCH at pre- to post-treatment.
Study Selection
A total of 12 original studies included in the 
final review had a sample size ranging from 20 to 
5615, 17, 18, 20, 21, 23-28, 30). The total sample of subjects 
to our hypothesis by two independent reviewers 
(M.A., Y.K.) via Medline using PubMed and Ovid SP, 
Web of Science, Cochrane Central Register of Con-
trolled Trials, and EMBASE, up to December 2016. 
The following medical subject headings [Mesh] were 
used to select the relevant studies for a final review 
and meta-analysis: SCH [Mesh] OR SCH [Mesh] 
AND thyroxin [Mesh] OR 3, 5, 3’, 5’-tetraiodothyro-
nine [Mesh] OR T4 [Mesh] AND CIMT [Mesh] OR 
CIMT [Mesh] OR carotid atherosclerosis [Mesh] AND 
(random [Free Item] OR randomized controlled trials 
[Free Item] OR RCTs [Free Item]). Furthermore, the 
Fig.1. PRISMA search Flow Diagram for CIMT values at baseline in SCH and EU subjects as well as CIMT 
values at pre-to-post Thyroxin treatment in SCH subjects.
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tia interface. Any type of disagreement in data collec-
tion was resolved by discussion with a fourth reviewer 
(Kandimalla, Y). In all clinical trials included in this 
meta-analysis, the confounding factors that may affect 
CIMT, for example, use of recent previous/present thy-
roid medications or other medications that affect thy-
roid hormones, any thyroid disease other than SCH, 
smoking, HTN, DM, CVD, stroke, chronic liver dis-
ease, and chronic kidney disease were balanced between 
subjects with SCH and EU controls by the respective 
authors of each included study. All studies in this 
review have clearly mentioned about the research 
approval of the institutional ethical committee and 
participants in the studies completed and signed the 
informed consent form.
Data Synthesis and Analysis
The baseline mean CIMT as well as the standard 
deviations of CIMT were extracted in subjects with 
SCH and EU controls. The mean CIMT values and 
standard deviations were also extracted in subjects 
with SCH at pre- and post-treatment with thyroxin. 
We used RevMan 5 free version to conduct the data 
analysis31). The overall variation among studies termed 
as heterogeneity was calculated by I2 (Tau2) statistics. 
The square root of this number is the estimated stan-
dard deviation of the underlying effects across studies. 
The estimate of the between-study variance can be 
measured via a fixed- or random-effect model. We cal-
culated the weighted mean difference (WMD) or the 
standardized mean difference (SMD) with a 95% con-
fidence interval (CI) to calculate the pooled effect size 
using a fixed- or random-effect model as appropriate. 
Under a fixed-effect model, we assume that there is 
one true effect size that is shared by all the included 
studies. It follows that the combined effect is our esti-
with SCH was (n?380) and that with EU controls 
was (n?367). First, we screened 38 studies that dis-
cussed CIMT values in subjects with SCH and EU at 
baseline. Of these 38 studies, only 12 studies were 
clinical trials that discussed the treatment of SCH 
with thyroxin and measured CIMT values at pre- and 
post-treatment with a follow-up period. We excluded 
all other studies (n?26) as these were case control, 
and/or cross-sectional, case reports/editorials, and 
none of these studies discussed the treatment of sub-
jects with SCH. Among these finally selected 12 stud-
ies for review, 11 studies were included in the meta-
analysis as the study by Köroglu et al. 201224) did not 
report any mean CIMT values at pre- and post-treat-
ment with thyroxin.
Data Extraction and Quality Assessment
Three authors (Machavarapu, A; Saxena, A; 
Nguyen, M) extracted the data on an excel sheet inde-
pendently from eligible studies related to subjects with 
SCH, EU controls, as well as the treatment of subjects 
with SCH. The data extracted included first author 
last name, publication year, study design, country of 
origin, study subjects’ age, sample size, gender, cut-off 
TSH value to diagnose SCH, systolic blood pressure 
(SBP), diastolic blood pressure (DBP), lipid levels [total 
cholesterol (TC), triglycerides (TG) high-density lipo-
protein (HDL), low-density lipoprotein (LDL), TSH], 
and CIMT in subjects with EU and SCH at baseline 
as well as at pre- and post-treatment with thyroxin. In 
different studies selected for a review, different bio-
chemical and hormones assays were used to measure 
all classes of lipids and TSH levels. All studies used 
Doppler ultrasound of carotid arteries to measure 
CIMT. CIMT was assessed as the distance between 
the lumen– intima interface and the media –adventi-
Fig.2. Risk of bias graph for randomized controlled trials using the Cochrane risk of bias tool. 
Review authors’ judgments about each risk of bias item presented as percentages across all 
included studies.
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values from pre- to post-treatment.
CIMT Values Among Subjects with SCH and EU at 
Baseline
The 9 clinical trials reported differences of CIMT 
values among subjects with SCH and EU controls at 
baseline (SCH, n?280; EU, n?263). There was a sta-
tistically significant heterogeneity among studies 
(I2?65%; p?0.004). A random-effect model was used 
to calculate the pooled WMD and the overall WMD 
showed significantly higher CIMT values among sub-
jects with SCH as compared to those with EU [WMD 
0.44 mm; 95% CI (0.14, 0.74); p?0.004] (Fig.4a).
mate of this common effect size. In contrast, under a 
random-effect model, we allow that the true effect 
could vary from study to study and we try to estimate 
the mean of a distribution of true effects. Large stud-
ies may produce more precise estimates of a true effect 
than small studies, but each study estimates a different 
effect size. Therefore, the weights assigned under a 
random-effect model are more balanced as compared 
with that in a fixed-effect model. WMD with a 95% 
CI of CIMT values was measured for subjects with 
SCH and EU at baseline. WMD with a 95% CI of 
CIMT was also measured for subjects with SCH at 
pre- and post-treatment periods with thyroxin. Statis-
tical heterogeneity was tested using Tau2 with p?0.05 
considered as significant.
Two authors (Khan, IM; Aziz, M) used the 
Cochrane risk of bias tool to determine the risk of a 
bias graph (Fig.2) and that of a bias summary (Fig.3) 
in individual studies per methodological quality of 
included clinical trials. The Cochrane risk of bias tool 
is based on the following items: Random sequence 
generation, allocation concealment, blinding of partici-
pant and personnel, outcome data blinding, incom-
plete outcome data, selective reporting, and other bias. 
A subgroup/sensitivity analysis was used to explore the 
potential sources of between-studies heterogeneity 
according to the type of studies, study quality by the 
JADAD score as a low (≤2 score) or high (≥3 score) 
range of quality score, BMI ?25 kg/m2, TSH values 
as ≤10 mIU/l and ?10 mIU/l, and duration of treat-
ment as less than 6 months and more than 6 months. 
Potential publication bias was assessed and represented 
graphically with funnel plots of WMD or SMD versus 
standard error32, 33). The decision to use the results of 
the Cochrane risk of bias assessment tool and publica-
tion bias among studies was taken by discussing with 
senior authors (Nasir, K; Kandimalla, Y; Veledar, E)
Results
Study Characteristics
Table 1 shows the characteristics of subjects with 
SCH and EU controls. All 12 studies discussed the 
comparison of CIMT values in subjects with SCH 
and EU at baseline as well as the effect of thyroxin 
treatment on CIMT reduction in subjects with SCH. 
However, only 9 out of 12 studies reported the mean 
CIMT values of subjects with SCH and EU controls 
at baseline and 11 out of 12 studies reported the effect 
of thyroxin treatment on CIMT reduction from pre- 
to post-treatment. Table 2 shows the JADAD score 
for the quality of each study, duration of follow-up, 
TSH and CIMT values at pre- and post-treatment, 
and change and percentage change in TSH and CIMT 
Fig.3. Risk of bias summary: Review authors’ judgments 
about each risk of bias item for each included study.
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Table 1. Characteristics of study population
Author(s),
Year Published
& Study Type
Country
Sample
(SCH/EU)
Age (yr)
(SCH/EU);
Female %
TSH cutoff
value
(mIU/l)
TSH (mIU/l)
at baseline
(SCH/EU)
CIMT (mm)
at baseline:
SCH/EU
Exclusion criteria used
SCH and EU
Groups matched
for
Monzani et al.
200418);
Clinical trial
Italy 45/32
37?11/
35?10
?3.6
6.03?8.4/
1.19?1.6
0.76?0.14/
0.63?0.07
Thyroid Rx., subjects ?55 yr, obese (BMI ?30 kg/
m2), smoking, HTN, DM, CVD, CRF, CLD.
sex, age, BMI
Duman et al.
200723);
Clinical trial
Turkey 20/20
37.0?12.6/
37.0?12.6 
?4.2 
10.9?5.8/
2.3?0.8
0.65?0.99/
0.54?0.10
Taking any medication, Obesity (BMI?30 kg/m2), 
DM, HTN, CHD, CLD, CRF, FH, PVD, age ?18 
years or ?60 years, smoking, menopause, pregnancy. 
sex, age. 
Adrees et al.
200920);
Clinical trial
Ireland 56/56
50?9/
NR
NR
13.2?4.5/
1.9?1.0
0.82?0.2/
NR
Hx. of IHD, TIA, HTN, DM, or impaired fasting 
glycaemia, smoking, coeliac disease, pernicious ane-
mia.
age, BMI. 
Kim et al.
200917);
Clinical trial
Korea 36/32
36.0?6.2/
36.1?5.4
?5.5 
11.48?4.70/
1.60?0.60
0.67?0.11/
0.57?0.08
Hx. of thyroid disease or Rx., thyroidectomy, or 
radioiodine therapy, DM, HTN, serum Creatinine 
?1.3 mg/dL, smoking, statin use, previous preg-
nancy in the last 1 year, postmenopausal state. 
gender, age,
BMI
Kebapcilar et al.
201015);
Clinical trial
Turkey 38/19
49.47?10.04/
49.95?8.12
?5.0
11.26?7.54/
1.48?1.12
0.64?0.13/
0.57?0.08
DM, CHD, CLD, CRF, other systemic diseases, 
morbid obesity, FH, cancer. MEDS: anti-hyperlipid-
emics, antihypertensives, acetylsalicylic acid, antihis-
tamines, corticosteroids, HRT, multivitamins, or 
excessive alcohol. 
age, smoking
habit, waist
circumference, 
BMI.
Cabral et al.
201130);
Clinical trial
Brazil 32/NR
47.59?8.4/
43.36?9.8
?4.0
6.79?2.0/
6.77?1.9
0.66?0.11/
NR
Hx. of previous thyroid disease, TSH ?12 mIU/ml, 
obesity, HTN, DM, CAD, CLD, CRF, alcohol use. 
MEDS?: amiodarone, corticosteroids, estrogens, lith-
ium, anti-lipids, diuretics, anti-diabetics, antihyper-
tensive, and drugs to treat obesity.
NR 
Koroglu et al.
201224);
Clinical trial
Turkey 30/NR
44.0?11.6/
47.9?14.6
NR
7.5?1.5/
6.8?1.4
NR/NR
CAD, CLD, CRF, chronic inflammatory disease, 
hypophyseal insufficiency, Thyroid Rx. in recent 3 
months, use of statins, use of HRT.
NR 
Akkoca et al.
201421);
Clinical trial
Turkey 20/20
34.47?1.43/
35.25?2.21
NR
8.97?1.1/
3.50?0.43
0.74?0.63/
0.39?0.72
Hx. of thyroid Rx. , HTN, DM, CAD, CLD, CRF, 
cancer, FH, use of lipid lowering drugs, BMI ?20 
kg/m2 or?30 kg/m2, smoking. 
Age, height,
weight, BMI
Unsal et al.
201425);
Clinical trial
Turkey 56/46
41.32?14.48/
36.07?10.58
?4.2
6.77?2.902/
1.65?0.913
0.533?0.112/
0.5?0.086
Hx. of thyroid disease or Rx, thyroidectomy, obesity, 
DM, HTN, CVD, CLD, CRF, radioiodine therapy, 
statin use, alcohol use. 
NR
Yazici et al.
201428);
Clinical trial
Turkey 43/30
35.2?10.7/
34.5?8.2
?4
6.0?1.4/
2.0?0.3
0.51?0.09/
0.48?0.04
DM, HTN, heart failure, IHD, valvular disease, 
CLD, CRF, rheumatological disease, malignancy. 
MEDS: antihypertensives, antihyperlipidemics, ace-
tylsalicylic acid, HRT. 
Sex, age, SBP,
DBP, BMI
Cerbone et al.
201626);
Clinical trial
Italy 39/39
9.18?3.56/
9.45?3.62; 
?4.5
6.30?1.01/
2.92?0.68
0.44?0.08/
0.44?0.06
Chronic diseases, chromosomal and genetic syn-
dromes, previous or current thyroid diseases, use of 
drugs that may interfere with thyroid function, pre-
vious irradiation in the neck region, detection of 
SCH at neonatal screening, familial history of genetic 
lipid disorders or early CVD
age, height,
BMI, SBP,
DBP, 
Niknam et al.
201627);
Clinical trial
Iran 25/25
35.9?7.6/
37.5?7.3
7.19?1.29/
2.4?0.55
0.56?0.09/
0.58?0.08
Rx. of hypothyroidism, CVD, CRF, CLD, malig-
nancies, or CVA, HTN, DM, obesity (BMI?30 kg/
m2), smoking, pregnancy, lactating women.
sex, age. 
SCH?Subclinical Hypothyroidism, NR?Not reported, Hx?History of, Rx?Treatment of, HTN?Hypertension, DM?Diabetes Mellitus, ATH 
Disease?atherosclerotic disease (e.g. CAD, PAD etc. ), CAD?Coronary Artery Disease, IHD?Ischemic Heart Disease, CHD?Coronary Heart Dis-
ease, CHF?Congestive Heart Failure, CLD?Chronic Liver Disease, CRF?Chronic Renal Failure, CARS?Coronary Artery Revascularization Surgery, 
TC?Total cholesterol, HCL?Hypercholesterolemia, CAH?congenital adrenal hyperplasia, HPRL?hyperprolactinemia, WC?Waist Circumference, 
FH?Familial Hypercholesterolemia, CD?Cushing’s disease, TIA?Transient Ischemic Attacks, HRT?Hormone Replacement Therapy, 
MNG?Multinodular Goiter, DBP?Diastolic Blood Pressure, SBP?Systolic Blood pressure. MEDS? use of any drugs that alter Thyroid function test. 
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0.61 vs. 0.36). We also conducted a subgroup analysis 
based on BMI groups. We calculated WMD with 
95% CI by excluding all the studies with BMI ?25 
kg/m2 (as an increase in BMI is related to an increase 
in CIMT). We used only those studies that reported a 
mean BMI of subjects with SCH and EU as ?25 kg/
m2. CIMT was still significantly higher in subjects 
with SCH as compared to EU [WMD 0.51; 95% CI 
(0.14, 0.89); p?0.008] with significant heterogeneity, 
I2?70%; p?0.005. As increasing age, smoking, hyper-
tension, diabetes, non-alcoholic fatty liver disease, dys-
lipidemia, polycystic ovarian disease, and menopause 
are related to increased CIMT and increased CVD 
risks, we removed all studies that discussed subjects 
with SCH and EU controls with one or multiple of 
these risk factors. The remaining 8 studies still showed 
a significant increase in CIMT among subjects with 
A subgroup analysis was also conducted by con-
sidering TSH cut-off values as ≤10 mIU/l and ?10 
mIU/l in subjects with SCH and comparing their 
CIMT values with those of EU controls at baseline. 
Subjects with SCH with TSH ≤10.0 mU/l exhibited a 
near significant increase in CIMT as compared to EU 
controls at baseline; WMD was 0.36 mm with 95% 
CI (?0.01, 0.73); p?0.06 with significant heteroge-
neity; I2?68%; p?0.009. However, WMD between 
subjects with SCH with a mean TSH ?10.0 mU/l 
and EU controls was 0.61 with 95% CI (0.13, 1.10); 
p?0.01, and heterogeneity was decreased to I2?56%; 
p?0.10. This shows that with a decreased between-
studies heterogeneity, subjects with SCH with TSH 
?10.0 mU/l exhibited a significantly higher WMD 
increase in CIMT as compared to SCH with TSH 
≤10.0 mU/l when compared to EU controls (WMD 
Table 2. Characteristics of SCH subjects: Pre-to-Post Treatment (INCLUDED ONLY STUDIES THAT DISCUSSED TREAT-
MNET OF SCH)
Authors
N (SCH): 
Pre-Rx/
Post-Rx; %
Females
JADAD
Score
Primary
disease
Rx.
given
Dose of 
Thyroxin 
(µg/day)
Duration
of Rx.
(Mo)
TSH (mIU/
L) in SCH 
(pre-Rx)
TSH (mIU/
L) in SCH 
(Post-Rx)
Change
%
change
CIMT
(mm) in
SCH
(Pre-Rx)
CIMT
(mm) in
SCH
(Post-Rx)
Change
%
change
Monzani et al.
200418)
23/23;
82%
4 SCH T4 25 6 6.03?8.4 1.32?1.7 ?4.71 ?78% 0.76?0.14 0.67?0.13 ?0.09 ?12%
Duman et al.
200723)
20/20;
100%
4 SCH T4 25 8 10.9?5.8 2.0?1.1 ?8.9 ?82% 0.65?0.99 0.55?0.08 ?0.1 ?15%
Adrees et al.
200920)
56/52;
100%
1 SCH T4 50 18 13.2?4.5 1.6?1.8 ?11.6 ?88% 0.82?0.2 0.71?0.2 ?0.11 ?13.4%
Kim et al.
200917)
36/28;
86.1%
3 SCH T4 67 18 11.48?4.70 1.26?3.30 ?10.22 ?89% 0.67?0.11 0.60?0.10 ?0.07 ?10%
Kebapcilar et al.
201015)
38/38;
82%
3 SCH T4 25-50 6 11.26?7.54 2.29?1.43 ?8.97 ?80% 0.64?0.13 0.63?0.12 ?0.01 ?1.6%
Cabral et al.
201130)
14/14;
100%
4 SCH T4 44.23 12 6.79?2.0 3.02?0.89 ?3.77 ?56% 0.66?0.11 0.66?0.15 0 0%
Köroglu et al.
201224)
30/30;
97%
4 SCH T4 50 6 7.5?1.5 3.6?0.6 ?3.9 ?52% NR NR NA NA
Akkoca et al.
201421)
20/20;
75%
3 SCH T4 NR 7 8.97?1.1 2.94?0.43 ?6.03 ?67% 0.74?0.63 0.43?0.32 ?0.31 ?42%
Unsal et al.
201425)
56/56;
91%
1 SCH T4 25-50 6 6.77?2.90 2.73?1.17 ?4.04 ?60% 0.53?0.11 0.51?0.13 ?0.02 2%
Yazıcı et al.
201428)
23/23;
98%
4 SCH T4 NR 6 5.9?1.2 1.7?0.9 ?4.2 ?71% 0.51?0.09 0.46?0.07 ?0.05 10%
Cerbone et al.
201626)
39/39;
51%
2 SCH T4 50 24 6.30?1.01 2.82?1.31 ?3.48 ?55% 0.44?0.08 0.46?0.07 0.02 4.5%
Niknam et al.
201627)
25/25;
60%
1 SCH T4 50 2 7.19?1.29 2.56?0.69 ?4.63 ?64% 0.56?0.09 0.57?0.08 0.01 2%
The JADAD score/scale or the Oxford quality scoring system, is a procedure to independently assess the methodological quality of a clinical trial. 
SCH?Subclinical Hypothyroidism, TSH?Thyroid stimulating hormone.
???????????
650
5%; p?0.39] and in subjects with SCH with a prior 
treatment TSH ≥10 mIU/l was [WMD ?0.35 mm; 
95% CI (?0.61, ?0.08); p?0.010; with heterogene-
ity, I2?21%; p?0.28]. Although WMD of a decrease 
in CIMT with thyroxin treatment was higher in sub-
jects with SCH with a prior treatment TSH ?10 
mIU/l as compared to those with TSH ≤10 mIU/l 
(WMD ?0.35 vs. ?0.30), this subgroup analysis indi-
cates that thyroxin treatment is effective in both groups 
of subjects with SCH based on a prior treatment TSH 
level (i.e., TSH as ≤10 mIU/l or TSH ≥10 mIU/l) in 
significantly reducing CIMT. In a subgroup sensitivity 
analysis by the duration of follow-up with thyroxin 
treatment keeping 6 months of treatment as cut-off, 
subjects with ?6 months’ thyroxin treatment had a 
higher decrease in CIMT from pre- to post-treatment 
with WMD [?0.36.; 95% CI (?0.61, ?0.12); p? ?
0.004] with heterogeneity I2?0% (p?0.49), as com-
pared to subjects with ≤6 months’ thyroxin treatment 
with WMD [?0.28; 95% CI (?0.49, ?0.08); p? ?
0.007] with heterogeneity I2?24% (p?0.25). We also 
conducted a subgroup analysis based on the JADAD 
score. We excluded all low-quality studies with the 
JADAD score ≤2. In all studies with the JADAD 
score ≥3, WMD of a decrease in CIMT from pre- 
to post-treatment in subjects with SCH was [WMD 
?0.40 mm; 95% CI (?0.61, ?0.19); p?0.0002); 
with heterogeneity, I2?8%; p?0.37]. In a subgroup 
analysis, the test for the overall effect of CIMT reduc-
tion with thyroxin treatment was significant with Z? ?
5.54; p?0.00001; with heterogeneity I2?0%; p?0.50, 
and the test for subgroup differences was [Chi2?0.32, 
df?3 (p?0.96), I2?0%]. (Fig.5a).
Changes of Metabolic Parameters
Table 3 shows the differences in metabolic param-
eters between subjects with SCH and EU controls at 
baseline as well as after thyroxin treatment in subjects 
with SCH. As compared to EU controls, subjects with 
SCH as compared to EU controls [WMD 0.42; 95% 
CI (0.09, 0.75); p?0.01)] with significant heterogene-
ity, I2?68%; p?0.002. The test for the overall effect 
of CIMT differences in a subgroup analysis was sig-
nificant with Z?4.88; p?0.00001; with heterogene-
ity I2?64%; p?0.0001, and the test for subgroup dif-
ferences was [Chi2?0.80, df?3 (p?0.85), I2?0%]. 
(Fig.4b)
Effect of Thyroxin Treatment on CIMT Values in 
Subjects with SCH
All 12 studies discussed the effects of thyroxin 
treatment on CIMT reduction from pre- to post-
treatment in subjects with SCH (n?314) with the 
duration of treatment ranging from 2 to 24 months; 
however, 11 studies were included in the meta-analysis 
as one study by Koroglu et al. 201224) did not report 
the mean CIMT values in subjects with SCH at pre- 
and post-treatment with thyroxin. After treatment 
with thyroxin in subjects with SCH, there was a statis-
tically significant decrease in CIMT from pre- to post-
treatment. In a fixed-effect model, the pooled WMD 
of CIMT decrease in subjects with SCH from pre- to 
post-treatment with thyroxin was ?0.32 mm with 
95% CI (?0.47, ?0.16), p??0.0001 with heteroge-
neity, I2?2%; p?0.42. CIMT of SCH treated subjects 
was no longer different from matched EU subjects 
with WMD of 0.13 mm and 95% CI (?0.04, 0.30); 
p?0.14 and heterogeneity, I2?27%; p?0.20) (Data 
not shown). (Figs.5a & 5b)
A subgroup analysis was also conducted by con-
sidering prior thyroxin treatment TSH cut-off values 
as ≤10 mIU/l and ?10 mIU/l in subjects with SCH 
and calculating the mean decrease in CIMT with thy-
roxin treatment from pre- to post-treatment periods. 
WMD of a decrease in CIMT from pre- to post-treat-
ment in subjects with SCH with a prior treatment 
TSH ≤10 mIU/l was [WMD ?0.30 mm; 95% CI 
(?0.50, ?0.10); p?0.003); with heterogeneity, I2? ?
Fig.4a. WMD with 95% CI of CIMT in SCH and EU at baseline.
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changes in metabolic parameters in subjects with SCH 
at pre- to post-treatment with thyroxin along a treat-
ment follow-up period. As compared to pre-treatment 
with thyroxin, the levels of TC (WMD, ?0.53 mg/dl, 
95% CI (?0.97, ?0.09); p?0.02), TG [WMD, ?0.55 
mg/dl, 95% CI (?0.96, ?0.13); p?0.01], LDL [WMD, 
?0.57 mg/dl, 95% CI (?0.98, ?0.15); p?0.007], SBP 
[WMD, ?0.33 mmHg l, 95% CI (?0.62, ?0.05); 
p?0.02], and DBP [WMD, ?0.38 mmHg, 95% CI 
(?0.68, ?0.08); p?0.01] were significantly decreased 
SCH had a significant increase in the levels of TC 
[WMD, 0.71 mg/dl, 95% CI (0.23, 1.19); p?0.004), 
TG [WMD, 0.51 mg/dl, 95% CI (0.13, 0.90); p? ?
0.009], LDL [WMD, 0.63 mg/dl, 95% CI (0.30, 0.95); 
p?0.0001], SBP [WMD, 6.16 mmHg l, 95% CI (1.88, 
10.45); p?0.005], and DBP [WMD, 0.43 mmHg, 
95% CI (0.11, 0.76); p?0.009]. There was no sig-
nificant difference in the HDL level in subjects with 
SCH and EU at baseline [WMD, 0.02 mg/dl, 95% 
CI (?0.24, 0.27); p?0.90]. We also discussed the 
Fig.4b. Subgroup analysis: WMD with 95% CI of CIMT in SCH and EU at baseline.
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in different countries or research settings in heteroge-
neous populations.
Medication doses provided to subjects with SCH 
were not similar across the studies. To account for this 
variability, we conducted a meta-regression analysis 
and accounted for different dose-related information. 
Results showed that there was an inverse relationship 
between increasing medication dosage and low CIMT, 
but the association was not significant. For each unit 
increase in dose, CIMT decreased by 0.004 units (?: 
?0.004; 95% CI: ?0.03, 0.02; p?0.70). This could 
be due to the limited number of studies (n?9) 
included in the model.
Discussion
We conducted a meta-analysis to demonstrate 
the differences of CIMT values between subjects with 
SCH and EU controls at baseline. We also provided 
evidence of the effect of thyroxin treatment on CIMT 
reduction in subjects with SCH from pre- to post-
treatment. The main results of this meta-analysis were 
as follows: (1) CIMT was significantly higher in sub-
jects with SCH as compared to matched EU controls 
at baseline. (2) Thyroxin treatment in subjects with 
SCH was related to a significant reduction in CIMT 
values from pre- to post-treatment over a follow-up 
period and CIMT values in post-treated subjects with 
SCH were no longer different from CIMT values of 
matched EU controls. (3) More than 6 months of thy-
roxin treatment showed a higher reduction in CIMT 
values as compared to less than 6 months of thyroxin 
treatment. (4) As compared to EU controls, SCH was 
also associated with a significant increase in TC, TG, 
LDL, SBP, and DBP. (4) Thyroxin treatment in sub-
jects with SCH was related to a significant reduction 
in TC, TG, LDL, SBP, and DBP from pre- to post-
treatment over a follow-up period. (5) Neither SCH 
was associated with a low level of HDL nor the treat-
at post-treatment with thyroxin. Thyroxin treatment 
did not have any significant effect in increasing the 
HDL levels as there was no significant change in HDL 
(WMD, 0.03 mg/dl, 95% CI ?0.16, 0.22; p?0.75) 
in subjects with SCH from pre- to post-treatment 
with thyroxin.
Assessment of Publication Bias
We included at least 3 studies from a total of 12 
studies that were eligible for this meta-analysis, which 
discussed the comparison of CIMT values. To assess 
any publication bias, we generated funnel plots of 
effect estimates against their standard errors (on a 
reversed scale) using free version of Review Manager 
software 5 (RevMan) (Figs.6 and 7). We assessed the 
potential risk of publication bias through visual analy-
sis of funnel plots. The studies reporting CIMT values 
in subjects with SCH and EU controls at baseline 
(n?9) generated a roughly symmetrical funnel plot 
indicating a positive standardized mean difference, 
while 2 studies were published with significantly 
higher values for a standardized mean difference and 1 
study with a lower standardized mean difference. There 
is little possibility of publication bias toward reporting 
lower CIMT among EU controls. Studies reporting 
CIMT from pre- to post-treatment with thyroxin in 
subjects with SCH produced a symmetrical funnel 
plot with a relatively low SE hinting at a low risk of 
publication bias (Higgins 2011). One should be mind-
ful that interpreting a funnel plot is subjective and an 
asymmetric funnel plot could be generated due to 
variability in selected sources, and it is not necessary 
that an actual publication bias can lead to an asym-
metrical funnel plot. We attempted to avoid bias in 
study selection by defining our search criteria a priori. 
These are discussed in detail under sensitivity analysis 
as well as in limitations and strengths of the study. We 
also addressed location bias by searching multiple 
databases, which included studies that were conducted 
Fig.5a. WMD with 95% CI of CIMT pre- to post-thyroxin Rx. in subjects with SCH.
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clinical CVD outcomes, such as heart failure progres-
sion with less evidence in the oldest old population41, 42). 
Rodondi et al. showed in a meta-analysis that SCH 
was associated with an increased risk of CHD43). In 
another meta-analysis of 11 prospective cohort stud-
ies, Rodondi et al. showed that SCH was associated 
with an increased risk of coronary heart disease 
(CHD) events and mortality. Such risk was greater 
among those with higher TSH levels, predominantly 
among those with a TSH level ≥10 mIU/L44). Accord-
ment of SCH caused a significant increase in the 
HDL level.
There is an increasing body of literature associat-
ing SCH with possible subclinical as well as clinical 
CVD outcomes15, 17, 18, 20-28, 34). The subclinical CVD 
outcome can be presented as increased inflammatory 
markers, risk of hypertension, lipid disorders, 
increased CIMT, endothelial dysfunction, and arterial 
stiffness17, 18, 22-26, 28, 35-40). Furthermore, some studies 
emphasized a positive association between SCH and 
Fig.5b. Subgroup analysis: WMD with 95% CI of CIMT in subjects with SCH at pre- to post-treatment with thyroxin.
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mIU/L, and followed an individualized approach in 
young patients with SCH (?70 years) with TSH ≤10 
mIU/L depending upon the presence and absence of 
symptoms of SCH. These guidelines recommended 
following the age-specific local reference ranges for 
serum TSH levels to decide in taking a step to treat 
subjects with SCH or simply follow-up with monitor-
ing of TSH in both situations55). Our meta-analysis 
showed a significant increased CIMT in subjects with 
SCH versus EU controls only at TSH values of ?10.0 
mIU/l, but showed a near significant increase in 
CIMT at TSH values of ≤10.0 mIU/l. However, this 
review emphasizes thyroxin treatment of subjects with 
SCH at any level of TSH, because such treatment has 
a significant effect on CIMT reduction both at a prior 
treatment TSH ≤10.0 mU/l as well as TSH ?10.0 
mU/l (Fig.5b). We also observed that subjects with 
SCH with a prior treatment TSH ?10.0 mU/l exhib-
ited a significantly higher WMD decrease in CIMT as 
compared to SCH with a prior treatment TSH ≤10.0 
mU/l (WMD ?0.35 vs. ?0.30), but both showed a 
significant CIMT reduction from pre- to post-treat-
ment. Some studies report against treating SCH 
because these studies did not find any evidence of 
SCH association with CVD outcomes at any level of 
TSH meeting SCH diagnosis. The study by Cappola 
et al. did not find any association between SCH and 
incidence and prevalence of atherosclerotic disease, as 
well as showed no significant positive effect on CVD 
outcome with thyroxin treatment56).
ing to some studies, SCH is not only related to worse 
CVD outcomes but also associated with pregnancy 
outcomes, infertility, other neuropsychiatric issues, 
and even cancer mortality45, 46). However, few studies 
failed to demonstrate such association between SCH 
and CVD outcomes47). Capola et al. showed a strong 
association between SCH and atrial fibrillation but 
did not support the association between SCH with 
other CVD-related morbidity and mortality48, 49). The 
main reason for the lack of evidence could be the use 
of a small sample size. The main mechanism of devel-
opment of CVD in SCH could be related to low-
grade chronic inflammation, abnormal lipid profile, 
insulin resistance, oxidative stress, arterial stiffness, and 
endothelial dysfunction38, 50-52). Moreover, these risk 
factors are accelerated in case of progression of SCH 
to overt thyroid disorders because there is a minimum 
of 2 to 5% per year to a maximum of 5 to 8% per 
year risk of progression of SCH to overt hypothyroid-
ism depending on the degree of serum TSH eleva-
tion53-55).
There is also an increasing controversy on whether 
or not subjects with SCH should be treated. Most 
research workers agree with treating SCH with persis-
tent serum TSH ≥10.0 mIU/L and following an indi-
vidualized therapy for those with TSH ?10.0 mIU/
L54). This is because the risk of CVD increases as the 
TSH level increases beyond 10 mIU/L. The 2013 
ETA Guidelines recommended thyroxin treatment of 
young patients with SCH (?70 years) if TSH ≥10 
Table 3. Metabolic Parameters at baseline in Subclinical Hypothyroid (SCH) subjects and Euthyroid (EU) controls and at Pre-and-
Post Rx with thyroxin in SCH subjects.
Metabolic Parameters at baseline b/w SCH and EU groups Changes of Metabolic Parameters at pre-and-post thyroxin Rx in SCH
Studies
#
Sample size
(SCH/EU)
WMD
(95%CI)
I2 Statistic
%; P
P value
# of
studies
Sample size SCH
(Pre-Rx/Post-Rx)
WMD
(95%CI)
I2 Statistic
%; P
P value 
TC 11 324/321
0.71
[0.23, 1.19]
87%;
0.00001
0.004 10 299/295
?0.53
[?0.97, ?0.09]
85%;
0.00001
0.02
TG 11 324/321
0.51
[0.13, 0.90] 
81%;
0.00001
0.009 10 299/295
?0.55
[?0.96, ?0.13]
83%;
0.00001
0.01
LDL 12 380/367
0.63
[0.30, 0.95] 
78%;
0.00001
0.0001 10 299/295
?0.57
[?0.98, ?0.15]
83%;
0.00001
0.007
HDL 12 380/367
0.02
[?0.24, 0.27]
65%;
0.0009
0.90 8 224/220
0.03
[?0.16, 0.22]
0%;
0.57
0.75
SBP 8 265/258
6.16
[1.88, 10.45]
62%;
0.009
0.005 6 209/205
?0.33
[?0.62, ?0.05]
52%;
0.07
0.02
DBP 8 265/258
0.43
[0.11, 0.76] 
69%;
0.002
0.009 6 209/205
?0.38
[?0.68, ?0.08]
56%;
0.04
0.01
TC?Total cholesterol, TG?Triglycerides, LDL?Low density lipoprotein, HDL?High density lipoprotein, SBP?Systolic Blood Pressure, 
DBP?Diastolic Blood Pressure.
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healthy young subjects. A meta-analysis by Goa et al. 
showed that SCH was associated with only SBP but 
not DBP34), but a meta-analysis by Cai et al.60) and 
the present meta-analysis showed that SCH was sig-
nificantly associated with higher SBP as well as higher 
DBP when compared with matched EU controls. Fur-
thermore, this meta-analysis also observed a significant 
decrease in both SBP (p?0.02) and DBP (p?0.01) 
with thyroxin treatment. This evidence suggested that 
subjects with SCH are at a significantly higher risk of 
subclinical CVD risk factors and can obtain benefits 
from in time long-term thyroxin treatment.
The strengths of the present meta-analysis are as 
follows: (1) We defined a strict inclusion and exclu-
sion criteria. (2) We conducted a different subgroup 
analysis to reduce heterogeneity and publication bias. 
(3) We also conducted an analysis for CIMT differ-
ences in subjects with SCH and EU controls after 
removing all studies that used subjects with any other 
conditions, which can potentially affect CIMT; for 
example, subjects with a history of smoking, hyper-
tension, and diabetes, obese with non-alcoholic fatty 
liver disease, with BMI ?25 kg/m2, subjects with Poly-
cystic Ovary Syndrome (PCOS); the results were still 
significant. (4) We conducted the dose meta-regres-
sion, which showed that an increase in each unit thy-
roxin dose has an addictive effect on CIMT reduction, 
although the model was not significant due to the lim-
ited number of studies included in the model.
The present meta-analysis has the following limi-
tations: (1) Most of the clinical trials discussing the 
treatment of subjects with SCH were not double-
blind, randomized controlled trials; however, such 
Our meta-analysis provided a strong evidence of 
increased subclinical CVD risks as increased CIMT, 
higher-level atherogenic lipids, and increased SBP and 
DBP in subjects with SCH. An increase in CIMT was 
significantly correlated with an increase in the level of 
atherogenic lipids. The altered lipid levels could be the 
major mechanism causing early atherosclerotic vascu-
lar changes in subjects with SCH. In all subgroup 
analyses, the association between increased CIMT in 
subjects with SCH remained significant except in sub-
jects with SCH with a mean TSH ≤10.0 mIU/l, 
where SCH was no longer associated with an increased 
CIMT. Furthermore, we found a greater improvement 
in CIMT values in subjects with SCH with a thyroxin 
treatment duration of more than 6 months versus less 
than 6 months (WMD of CIMT reduction ?0.36 vs. 
?0.28). Many studies vote for a lifelong treatment 
with thyroxin and a regular monitoring of thyroid 
function tests for clinical/overt hypothyroidism; how-
ever, no robust evidence exists regarding the duration 
of long-term treatment of otherwise healthy subjects 
with SCH. Moreover, some studies suggest little or no 
symptomatic benefit from the treatment of SCH57-59). 
According to the 2013 SCH treatment guidelines by 
Pearce et al., there is emphasis on starting the treat-
ment of SCH if a patient has signs and symptoms or 
other conditions, such as diffuse or nodular goiter, 
diabetes, dyslipidemia, or TSH ?10 mU/l, and if there 
is an improvement in symptoms, then to consider a 
lifelong treatment55). Our meta-analysis also showed a 
significant risk of an increase in CIMT and dyslipid-
emia especially at TSH ?10.0 mU/l and recommended 
the start of thyroxin treatment in SCH in otherwise 
Fig.6. Funnel plot of CIMT values in subjects with SCH and EU at baseline.
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and, therefore, are more likely to be missed in the 
search for relevant trials. All these types of biases are 
more likely to affect studies with smaller participants 
to a greater degree than large trials.
Conclusion
In summary, this meta-analysis suggests that 
there is a strong association of SCH and increased 
CIMT, along with dyslipidemia and incre ased SBP 
and DBP. Such association has been proven by many 
other studies. The increased CIMT could be related to 
the associated increase in TSH level, dyslipidemia, 
obesity, and hypertension. This meta-analysis also sug-
gests that thyroxin treatment has significant beneficial 
effects on CIMT reduction, weight, hypertension, and 
a positive improvement in lipids, especially thyroxin 
treatment longer than 6 months. Double-blind, ran-
domized controlled clinical trials with a longer dura-
tion of follow-up are needed to clearly delineate the 
risk of SCH with CVD risk factors.
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approach would be linked with a less bias. (2) There 
was significant heterogeneity among the studies dis-
cussing baseline differences among CIMT values in 
SCH and EU controls, although a subgroup analysis 
was conducted to calculate the less biased association 
between SCH and CVD risk factors. The main rea-
sons for heterogeneity would be related to the differ-
ences across the studies included in the review, such as 
great variations in sample size, type of study popula-
tion used, study design, different TSH cut-off value to 
diagnose SCH, differences in inclusion and exclusion 
criteria, the method of TSH and CIMT measure-
ments, and different confounding factors used for 
adjustment. (3) The duration of treatment was quite 
broad ranging from 2 months to 24 months, which 
can potentially create a bias, although we conducted a 
subgroup analysis keeping the cut-off treatment dura-
tion as 6 months and noticed that the benefit of CVD 
risks is greater with the treatment duration longer 
than 6 months. Randomized controlled clinical trials 
with longer treatment durations are needed to verify 
these changes. (4) We could not conduct a subgroup 
analysis of specific gender’s (females vs. males) risk of 
SCH with CIMT changes because some studies did 
not clearly provide such information. (5) The studies 
used in this meta-analysis used a broad age range, 
which could be another source of heterogeneity. (6) 
Heterogeneity could be due to a selection or language 
bias as we used articles from all languages; citation 
bias as “negative” studies are quoted less frequently 
Fig.7. Funnel plot of CIMT pre- to post-thyroxin Rx. in subjects with SCH.
Abbreviations: SCH: Subclinical hypothyroidism/Subclinical hypothyroid, EU: Euthyroid/
Controls
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